Combinatorial therapies consisting of radiation therapy with systemic therapies, particularly
chemotherapy and targeted therapies, have moved the needle to augment disease control …

CDK4/6 inhibitors combined with endocrine therapy prolonged survival in hormone receptor
(HR)-positive and HER2-negative advanced breast cancer. We investigated whether …

Background/Objectives: In Romania, breast cancer is the second most common cancer, the
third leading cause of cancer death, and the most prevalent cancer overall. De novo …

Abstract Purpose: CDK4/6 inhibitors require meticulous monitoring due to their potential to
cause hematological toxicities and hepatotoxicity. This study evaluates the safety of …

Background. The use of locoregional radiotherapy (RT) in patients with advanced ER-
positive, HER2-negative breast cancer remains a topic of ongoing debate. In this study, we …

Abstract Objectives Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have significantly
improved the survival of patients with hormone receptor-positive HER2-negative advanced …

Background In patients diagnosed with estrogen receptor (ER)-positive, human epidermal
growth factor receptor 2 (HER2)-negative advanced breast cancer, bone metastases …

We read the article by Kubeczko et al. titled ''Safety and Feasibility of Cyclin-dependent
Kinase 4/6 Inhibitors (CDK4/6i) Treatment Combined with Radiotherapy (RT) in Patients with …